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Methicillin-resistant Staphylococcus aureus (MRSA) has been
a common nosocomial pathogen since the 1960s and
has become a major problem in hospitals worldwide. In
2007, the European Antimicrobial Resistance Surveillance
System, a free network that connects more than 600 labo-
ratories in 31 European countries, reported an incidence of
MRSA bloodstream infection (BSI) per 100 000 patient-days
ranging from 0.2 in Sweden to 24.4 in Portugal [1]. A
meta-analysis showed that BSIs due to MRSA are associated
with almost two-fold higher mortality than those due to
methicillin-susceptible S. aureus [2]. Costs were significantly
higher for MRSA BSI than for methicillin-susceptible S. aur-
eus BSI [3].
Therefore, patients and the public increasingly view rates
of hospital-acquired MRSA as indicators of quality of patient
care. Detection and eradication of MRSA are becoming
public health priorities worldwide [4,5]. There has been
much debate about the evidence and cost-effectiveness of
various infection control policies in controlling MRSA. A
multidisciplinary approach should be employed in all set-
tings, including hand hygiene programmes, active surveillance
cultures, training of and feedback to healthcare workers,
bundles for ventilator-associated pneumonia and central
venous catheter-related infections, and environmental pro-
grammes [6,7]. A second, even more essential, aspect of
the management of MRSA is the treatment of serious infec-
tions, which must be prompt and efficacious in order to
allow rapid microbiological clearance and successful manage-
ment of the infection. It is also important to maintain
appropriate and constant antibiotic serum concentrations
[8–10]. Therapy for MRSA infections has to be decided
individually, with consideration of the susceptibility patterns,
source of the infection, presence of metastatic sites of
infection, comorbidities, and history of patient allergies. A
number of questions remain unsolved for the treatment of
severe MRSA infections (BSI, endocarditis, osteomyelitis,
and pneumonia). Although the glycopeptides still constitute
the drugs of choice, there are several concerns about the
treatment of MRSA infections: reports of clinical failure with
vancomycin treatment regardless of in vitro susceptibility;
increasing reports of strains with reduced vancomycin sus-
ceptibility; difficulty in therapeutic dosage monitoring; and
lack of evidence on the efficacy of combination therapy.
Moreover, in recent years, pharmaceutical companies have
curtailed antibiotic production. Linezolid, daptomycin and
tigecycline are the only three really innovative drugs for the
treatment of MRSA infections produced in the last
20 years.
At present, although the availability of linezolid, daptomy-
cin and tigecycline has definitely improved options for the
treatment of MRSA infections, the use of these antibacterials
should be carefully monitored, to avoid the future spread of
resistance. In addition, the therapeutic roles of the glycopep-
tides and the relevance of MICs need redefining. The selec-
tion of multidrug-resistant MRSA would have significant
consequences at the individual level (i.e. increased risk of
infection in a colonized patient) and at the institutional level
(i.e. increased risk of cross-transmission among hospitalized
patients, environmental contamination, and spread of resis-
tance in the community). For the updating of existing guide-
lines, new trials are needed to compare these new drugs for
the treatment of severe infections due to MRSA. Neverthe-
less, major efforts should be focused on improving specific
guidelines for hospital antibiotic use and infection control
measures to reduce the nosocomial spread of multidrug-
resistant MRSA strains.
Interestingly, although specific guidelines for the manage-
ment of MRSA infections have been published in many
European countries, there is no common agreement, and
treatment is still heterogeneous [11–13]. For certain clinical
practices in the management of MRSA, e.g. the use of
older drugs, combination therapy, intravenous–oral switch,
and duration of treatment, clear evidence does not exist.
Therefore, a large survey was proposed to canvass current
opinions and practice in the management and treatment of
MRSA infection among practitioners across Europe, concen-
trating on some of these controversial areas. An expert
faculty developed a series of questions and gave their own
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opinions anonymously on these topics. All registered dele-
gates of the 19th European Conference of Clinical Microbi-
ology and Infectious Diseases received a web-based
questionnaire covering the same topics on 16 and 29 April
2009. The authors analysed answers from 381 European
respondents, comparing them with the faculty’s responses.
The questions were focused on various aspects of the
practical treatment of MRSA infections, including preven-
tion, clinical decision-making and empirical therapy, use of
combination therapy, outpatient treatments, factors influ-
encing the selection of antibiotics, and duration of therapy.
Treatments for skin infection, BSI and pneumonia were
specifically addressed. The survey, whose results follow in
this supplement, shows considerable variation in opinion,
from clear consensus in some areas to significant heteroge-
neity in others.
The survey has been useful in identifying areas where
practice can be improved, e.g. in reducing the number of
line-associated MRSA bacteraemias; in identifying where edu-
cation may be valuable, e.g. in differentiating colonization
from infection; and where further research would be helpful,
e.g. in defining the role of older antibiotics. The survey may
well help in the development of pan-European guidelines.
The report provides insight into aspects of routine clinical
management of MRSA infection that may need to be
improved, and suggests areas to be covered by future epide-
miological and clinical studies. Such publications of opinion
and practice are useful for defining what is known about a
subject, what is being done, and what needs to be done, and
as such they can help inform scientists about the direction
that their work should be taking.
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